NCT06735495View on ClinicalTrials.gov

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
B-Cell Lymphoblastic Leukemia/Lymphoma
Interventions
DRUG

CD19&CD22 bispecific CAR-T cells

Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER